DDInter1907 DDInter922
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.[A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies.[A214280, A214295] On January 16, 2024, Iinebilizumab also received Health Canada approval for the same indication.
Ustekinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Ustekinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Ustekinumab {u} may lead to a major life threatening interaction when taken with {v} Sarilumab
Ustekinumab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Ustekinumab may lead to a major life threatening interaction when taken with Sarilumab
Ustekinumab may lead to a major life threatening interaction when taken with Natalizumab